Literature DB >> 2289406

Modelling the Helsinki Heart Study by means of risk equations obtained from the PROCAM Study and the Framingham Heart Study.

G Assmann1, H Schulte.   

Abstract

Data from the Prospective Cardiovascular Münster (PROCAM) study have been used to develop a mathematical model that accurately predicts the outcome of treatment in a primary prevention study (the Helsinki Heart Study). The PROCAM study identified 8 major risk factors for coronary heart disease: age, total plasma cholesterol level, plasma high density lipoprotein (HDL)-cholesterol level, systolic blood pressure, smoking, diabetes, angina pectoris, and a family history of myocardial infarction. A single risk factor such as total plasma cholesterol level is not sufficiently sensitive to identify individuals at high risk of coronary heart disease. The total cholesterol:HDL-cholesterol ratio is recommended for clinical use. On the basis of these data, a primary prevention strategy for coronary heart disease in West Germany has been proposed to optimise the cost-effectiveness of such treatment. Future research should focus on the identification of feasible and sensitive risk factors for coronary heart disease. Fibrinogen and apolipoproteins have already attracted interest in this regard but more definitive studies are required to confirm their role as risk factors for coronary heart disease.

Entities:  

Mesh:

Year:  1990        PMID: 2289406     DOI: 10.2165/00003495-199000401-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  8 in total

1.  Coagulation factors and the progress of coronary heart disease.

Authors:  L Balleisen; H Schulte; G Assmann; P H Epping; J van de Loo
Journal:  Lancet       Date:  1987-08-22       Impact factor: 79.321

2.  Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study.

Authors:  T W Meade; S Mellows; M Brozovic; G J Miller; R R Chakrabarti; W R North; A P Haines; Y Stirling; J D Imeson; S G Thompson
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

3.  Plasma fibrinogen--a major coronary risk factor.

Authors:  M C Stone; J M Thorp
Journal:  J R Coll Gen Pract       Date:  1985-12

4.  Fibrinogen and risk of cardiovascular disease. The Framingham Study.

Authors:  W B Kannel; P A Wolf; W P Castelli; R B D'Agostino
Journal:  JAMA       Date:  1987-09-04       Impact factor: 56.272

5.  Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society.

Authors: 
Journal:  Eur Heart J       Date:  1987-01       Impact factor: 29.983

6.  Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.

Authors:  V Manninen; M O Elo; M H Frick; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen
Journal:  JAMA       Date:  1988-08-05       Impact factor: 56.272

7.  Fibrinogen as a risk factor for stroke and myocardial infarction.

Authors:  L Wilhelmsen; K Svärdsudd; K Korsan-Bengtsen; B Larsson; L Welin; G Tibblin
Journal:  N Engl J Med       Date:  1984-08-23       Impact factor: 91.245

8.  The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society.

Authors: 
Journal:  Eur Heart J       Date:  1988-05       Impact factor: 29.983

  8 in total
  1 in total

1.  Effects of simvastatin 20 mg/d on serum lipid profiles in Japanese hyperlipidemic patients: A prospective, open-label pilot study.

Authors:  Hiroshi Yoshida; Hidekatsu Yanai; Toru Shoda; Nobuyuki Furutani; Noriko Sato; Norio Tada
Journal:  Curr Ther Res Clin Exp       Date:  2005-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.